Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (MIRV) in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer With Expression of Folate Receptor α（FRα）

NCT07690332 is registered in ClinicalTrials.gov with NING LI-GYN as lead sponsor.

NCT NCT07690332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07690332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (MIRV) in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer With Expression of Folate Receptor α（FRα）
Lead sponsor
NING LI-GYN
Phase
Observational
Overall status
Not yet recruiting
Start date
July 20, 2026
Completion date
September 30, 2028
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancers, ovarian cancer, primary peritoneal cancer